HYDROXYUREA (hydroxyurea) by Leadingtac Pharmaceutical is 12. Approved for antimetabolite [epc]. First approved in 2020.
Drug data last refreshed 20h ago
12.1 Mechanism of Action The precise mechanism by which hydroxyurea produces its antineoplastic effects cannot, at present, be described. However, the reports of various studies in tissue culture in rats and humans lend support to the hypothesis that hydroxyurea causes an immediate inhibition of…
Worked on HYDROXYUREA at Leadingtac Pharmaceutical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Antimetabolite
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa
Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda ( BRAINSAFE-II )